Phentermine vs Ozempic: Different Drug Classes, Different FDA Approvals

This head-to-head evidence review is part of Weight Loss Rankings’ living editorial database — 300+ research articles and 190+ clinically-reviewed GLP-1 telehealth providers, sourced only from FDA prescribing information on DailyMed and peer-reviewed PubMed literature.

Phentermine and Ozempic are two of the most-searched prescription weight-loss drugs in the United States, but they share almost nothing pharmacologically. Phentermine is a 1959-approved sympathomimetic stimulant in the same chemical family as amphetamine, listed as a DEA Schedule IV controlled substance, and FDA-approved for short-term use only. Ozempic is a 2017-approved synthetic GLP-1 receptor agonist peptide, not a controlled substance, and FDA-approved for long-term type 2 diabetes therapy with a cardiovascular risk-reduction indication. Different mechanisms, different efficacy horizons, different safety profiles, different prices, different patients. This article walks each axis with the FDA-label and trial evidence behind it.

Two different drug classes, two different mechanisms

Phentermine and Ozempic do not belong to the same drug family. They sit on opposite sides of the modern obesity-medicine landscape.

Phentermine is a sympathomimetic amine first approved by the FDA in 1959. Chemically, it is α,α-dimethyl- phenethylamine — structurally an amphetamine analog with the alpha-methyl group that defines the amphetamine class. Its mechanism is presynaptic catecholamine release: phentermine triggers norepinephrine release in the hypothalamic appetite centers, with smaller effects on dopamine and serotonin. The net clinical effect is appetite suppression mediated by sympathetic-nervous-system activation. Side effects follow directly from the mechanism — elevated heart rate, elevated blood pressure, dry mouth, insomnia, and (in susceptible patients) anxiety and palpitations. Because of its amphetamine-family chemistry, phentermine is listed as a DEA Schedule IV controlled substance under 21 CFR 1308.14, with prescription-refill limits and DEA-registered-prescriber requirements that ordinary non-controlled drugs do not carry.^[11]

Ozempic is a once-weekly subcutaneous injection of semaglutide, a 31-amino-acid synthetic peptide analog of human glucagon-like peptide-1 (GLP-1). It was FDA-approved in December 2017 for type 2 diabetes glycemic control. Its mechanism is GLP-1 receptor agonism: semaglutide binds the GLP-1 receptor on pancreatic beta cells (increasing glucose-dependent insulin secretion), on alpha cells (suppressing inappropriate glucagon secretion), in the gut (slowing gastric emptying), and in the hypothalamic appetite centers (reducing food intake). Side effects follow from those mechanisms — nausea, vomiting, diarrhea, constipation, decreased appetite, and (rarely) acute pancreatitis and gallbladder disease. Ozempic is not a controlled substance and does not appear on any DEA schedule.^[9]

Those two mechanistic descriptions do not overlap. Phentermine is a CNS stimulant that lifts norepinephrine tone; Ozempic is a peptide hormone agonist that mimics the post-prandial incretin response. The two drugs share an outcome — reduced food intake — through entirely different molecular machinery.

FDA indications side-by-side

The FDA-approved indications, dose schedules, and durations of therapy diverge as sharply as the mechanisms. Verbatim from the current DailyMed labels:

The most consequential row in that table is the indication row. Phentermine’s FDA label authorizes short-term use only — typically interpreted as up to 12 weeks of continuous therapy. Ozempic’s label authorizes ongoing chronic therapy in adults with type 2 diabetes, with no upper time limit. That single difference determines almost every downstream comparison: which patients are appropriate, how insurance treats the script, how prescribers monitor side effects, and what the cost picture looks like across a full year of treatment.^[7][9]

Efficacy: short-term phentermine vs long-term semaglutide

The two drugs are studied on different timelines, which makes a clean head-to-head efficacy comparison impossible. The honest framing is the magnitude difference at each drug’s own FDA-approved horizon.

Phentermine: ~5% mean body-weight loss in 12 weeks

Phentermine was approved in 1959, well before the modern randomized-controlled-trial regulatory standard. The contemporary evidence base is a mix of older controlled trials, observational long-term cohort studies, and AACE/ACE clinical-practice-guideline reviews. Across this literature, mean total body weight loss on phentermine monotherapy at 12 weeks clusters around 3-5% of baseline body weight relative to placebo or diet-alone control — meaningful for a 12-week kickstart, but small compared to modern GLP-1 magnitudes. Hendricks et al. (2014, PMID 23736363) reported on long-term phentermine prescribing in a real-world obesity-clinic cohort and found that patients continuing phentermine beyond the FDA-label 12-week window maintained weight loss without evidence of addiction-typical behaviors, but the FDA label itself has not been updated to authorize long-term use.^[1]

The mechanistic ceiling is also relevant: phentermine’s appetite-suppressing effect tends to attenuate over weeks of continuous dosing as the sympathetic nervous system down-regulates, which is part of the rationale for the FDA-label short-term framing. The AACE/ACE 2016 guidelines (Garvey et al., PMID 27219496) acknowledge off-label long-term phentermine use under prescriber supervision in patients who respond and tolerate, but position phentermine as a short-term agent on the label and a niche long-term option in practice.^[6]

Semaglutide: -14.9% body weight at 68 weeks (Wegovy dose) and ~4-6 kg in T2D (Ozempic dose)

Semaglutide’s efficacy is measured in trials that ran for more than a year, because the molecule is approved for chronic therapy. The two reference data points:

• STEP-1 (Wilding 2021, PMID 33567185): Once-weekly semaglutide 2.4 mg (the Wegovy dose) vs placebo in 1,961 adults with overweight or obesity but without diabetes, for 68 weeks. Mean body-weight reduction was -14.9% on semaglutide vs -2.4% on placebo. Approximately 32% of semaglutide-treated patients reached at least 20% body- weight reduction. This is the magnitude every cross-class comparison ultimately benchmarks against.^[3]
• SUSTAIN-1 and the SUSTAIN program (PMID 28110911): Ozempic’s T2D monotherapy and add-on trials at 0.5 mg and 1.0 mg weekly produced mean HbA1c reductions of about -1.5% and mean body-weight reductions of about -4 to -6 kg at 30 weeks — secondary endpoints in a glycemic-control trial program, smaller in absolute magnitude than the Wegovy 2.4 mg dose tested in STEP-1 because the doses and indications are different.

For the cardiovascular axis, SUSTAIN-6 (Marso 2016, PMID 27633186) demonstrated a 26% relative reduction in major adverse cardiovascular events in T2D patients at high CV risk, and SELECT (Lincoff 2023, PMID 37952131) demonstrated a 20% relative reduction in MACE in obesity without diabetes at the semaglutide 2.4 mg dose. Phentermine has no published cardiovascular-outcomes trial that demonstrates MACE reduction.^[4][5]

Phentermine controlled-substance status (DEA Schedule IV)

The federal controlled-substance regime treats the two drugs very differently. Phentermine HCl is listed under 21 CFR 1308.14 as a Schedule IV controlled substance, alongside diazepam, alprazolam, tramadol, and other agents with recognized abuse potential but lower than Schedule III. The practical consequences for patients and prescribers:^[11]

• Prescriber requirements: Phentermine prescriptions must be written by a DEA-registered prescriber (physician, NP, PA, or other licensed mid-level with DEA registration in scope). Telehealth platforms that prescribe phentermine must verify DEA registration of every prescribing clinician and comply with the Ryan Haight Act in-person-exam rules (or the current telehealth flexibilities under the extended COVID-era waiver).
• Refill limits: Federal law caps Schedule IV prescriptions at a maximum of five refills within six months of the original prescription date. After five refills or six months (whichever comes first), the patient must obtain a new prescription. Many state pharmacy boards impose tighter limits.
• Interstate dispensing: Some states impose additional in-state-physician or in-state-pharmacy requirements on Schedule IV controlled substances. Patients who relocate mid-prescription may need a new prescription from a clinician licensed in the new state.
• Insurance and PBM treatment: Phentermine appears on most commercial formularies as a low-cost generic, but PBMs often flag it for quantity limits and duration-of-therapy review consistent with the FDA-label 12-week short-term framing.

Ozempic carries none of these constraints. Semaglutide is not a DEA controlled substance, so any licensed prescriber may write the script without a DEA registration overlay, refills follow ordinary state pharmacy rules without the federal Schedule IV cap, and interstate dispensing follows ordinary-prescription rules. The price of removing the DEA overlay is that the molecule itself is patented and brand-only — there is no FDA-approved generic semaglutide as of 2026, which is why Ozempic’s cash price is roughly 30-50 times phentermine’s.

Side effects: stimulant profile vs GLP-1 profile

Because the mechanisms diverge, so do the side-effect profiles. The two drugs do not share an adverse-event signature.

Phentermine (stimulant profile): The dominant adverse events follow directly from sympathetic-nervous-system activation. Verbatim from the Adipex-P §6 Adverse Reactions section: increased heart rate (palpitations, tachycardia), elevated blood pressure, dry mouth, insomnia, nervousness, restlessness, headache, dizziness, tremor, and constipation. Cardiovascular contraindications are stricter than for Ozempic: the label contraindicates phentermine in patients with known cardiovascular disease (coronary artery disease, stroke history, arrhythmias, uncontrolled hypertension, congestive heart failure), in patients taking MAO inhibitors within 14 days, in hyperthyroidism, and in glaucoma. Use during pregnancy is contraindicated.^[7]

Ozempic (GLP-1 profile): The dominant adverse events are gastrointestinal class effects: nausea (~16-20% on Ozempic 1.0 mg), vomiting (~8-9%), diarrhea (~9-11%), constipation (~5-7%), abdominal pain, and decreased appetite. Most GI events cluster in the dose-escalation period and attenuate over weeks. Less common but more serious warnings include acute pancreatitis, acute gallbladder disease, hypoglycemia (especially with insulin or sulfonylurea co-administration), acute kidney injury secondary to volume depletion from GI losses, diabetic retinopathy complications in T2D, and a boxed warning for thyroid C-cell tumors based on rodent data. The label contraindicates Ozempic in personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).^[9]

Cardiovascular safety is the most consequential difference. Phentermine’s sympathomimetic effect raises heart rate and blood pressure on average, and the label warns against use in patients with established CV disease. Ozempic, in contrast, holds an FDA cardiovascular risk-reduction indication in T2D with established CV disease — SUSTAIN-6 demonstrated a 26% relative reduction in MACE in that exact population. The two drugs are mirror images on the cardiovascular axis: phentermine is a sympathetic amplifier prescribers avoid in CV-comorbid patients; Ozempic is a cardioprotective agent prescribers reach for in CV-comorbid T2D patients.^[4]

Cost: phentermine ~$10-30/month, Ozempic $299-$1,000+/month

The price gap is the largest of any axis in this comparison. Three forces drive it: phentermine has been off-patent for decades and is a commodity generic; semaglutide is still under Novo Nordisk patent and has no FDA-approved generic or biosimilar; and phentermine is a small-molecule oral while semaglutide is a manufactured peptide injection with capital-intensive cold-chain logistics.

Phentermine cash pricing in 2026

Generic phentermine HCl 37.5 mg is one of the cheapest prescription weight-loss medications on the US market. Representative 2026 cash pricing for a 30-day supply:

• Walmart $4 generic list: phentermine HCl 37.5 mg is on the $4 / 30-day, $10 / 90-day generic list at most participating Walmart, Sam’s Club, and Neighborhood Market pharmacies.
• Mark Cuban Cost Plus Drugs: typically $10-15/month including the company’s flat-fee markup and shipping.
• Costco Member Prescription Program: typically $10-20/month for members; non-members pay slightly more.
• GoodRx and other coupon networks: typically $15-30/month at major retail chains using a printed or digital discount coupon.

Ozempic cash pricing in 2026

Ozempic is significantly more expensive at every tier:

• NovoCare Pharmacy direct-pay: $499/month for self-pay patients filling at NovoCare Pharmacy. The same flat self-pay price applies whether the patient fills 0.25 mg, 0.5 mg, 1.0 mg, or 2.0 mg pens.
• Retail list (WAC) without NovoCare: approximately $1,000/month at full retail before insurance or manufacturer discount programs (the wholesale acquisition cost has shifted over the past 2-3 years).
• Commercial insurance + manufacturer savings card: T2D patients with commercial coverage and a Novo Nordisk savings card frequently pay $25/month or less. Medicare and Medicaid beneficiaries are excluded from the savings card by federal law but generally have lower coinsurance because of plan formulary placement.
• Compounded semaglutide: the FDA shortage-list window that previously authorized broad compounding closed in February 2025, so compounded semaglutide is no longer the broad cash-pay workaround it was during the shortage.

Across a full year of treatment, the cost gap is not subtle. A 12-week course of generic phentermine at $15/month is roughly $45 total. A year of brand Ozempic at $499/month through NovoCare is roughly $6,000 total. The 100-fold difference is a real factor in patient decision-making, but it tracks a 3-fold magnitude difference in expected weight loss and a vastly larger cardiovascular-outcomes evidence base for Ozempic.

Combination therapy: Qsymia (phentermine + topiramate) as the middle ground

If phentermine is the short-term cheap stimulant and Ozempic is the long-term expensive GLP-1, Qsymia sits between them. Qsymia is the FDA-approved fixed-dose oral combination of phentermine plus topiramate extended-release, with FDA approval in July 2012 for chronic weight management — meaningfully different from phentermine monotherapy, which is short-term only.^[10]

The pivotal phase-3 evidence is CONQUER (Gadde et al., Lancet 2011, PMID 21481449), a randomized placebo-controlled trial of 2,487 adults with BMI 27-45 and at least two weight-related comorbidities. Mean body-weight reduction was -9.8% on the top Qsymia dose (15 mg / 92 mg) vs -1.2% placebo at 56 weeks. EQUIP (PMID 22051941) and SEQUEL (PMID 22158731) extended the evidence base to higher- BMI patients and 2-year follow-up.^[2]

Qsymia retains phentermine’s DEA Schedule IV status because of the phentermine component, and adds a Risk Evaluation and Mitigation Strategy (REMS) program for the topiramate component’s known teratogenicity (cleft lip and palate risk in first-trimester exposure). The result is a drug that achieves roughly two-thirds of the Wegovy magnitude (-9.8% vs -14.9%) at a substantially lower cash price than brand semaglutide, but with the controlled-substance and pregnancy-restriction overlays. For patients who tolerate oral therapy and want chronic-weight-management on-label coverage without the GLP-1 cost, Qsymia is the canonical non-GLP-1 option. See our dedicated Qsymia evidence review for the full trial data and dosing.

Which patient gets which drug

Working through the FDA indications, the trial data, the safety profiles, and the cost reality, the choice between phentermine and Ozempic sorts cleanly into patient profiles. Phentermine and Ozempic answer different clinical questions; they are not interchangeable.

• Short-term weight-loss kickstart in a patient with no CV comorbidity and no T2D: Phentermine. A 12-week generic course at $15/month, paired with caloric restriction and exercise counseling, is the canonical short-term option. Expect ~3-5% TBWL at 12 weeks. Re-assess at the end of the FDA-label window.
• Type 2 diabetes with or without weight to lose: Ozempic. On-label for glycemic control, with a strong cardiovascular outcomes evidence base in T2D + CV disease (SUSTAIN-6), and weight loss as a meaningful secondary effect at 1.0 mg or 2.0 mg weekly.
• Obesity without T2D, wants long-term FDA-approved chronic weight management: Wegovy, not Ozempic (and not phentermine). Wegovy is the same semaglutide molecule at the 2.4 mg dose with the chronic weight management indication; phentermine’s short-term label does not authorize long-term use. See the Wegovy vs Ozempic evidence review for that comparison.
• Established CV disease in an obese non-diabetic patient: Wegovy (anchored to SELECT, Lincoff 2023). Phentermine is contraindicated. Ozempic is not on-label for this population unless T2D is also present.^[5]
• Patient wants oral therapy, can tolerate stimulant side effects, no CV comorbidity: Qsymia (phentermine + topiramate ER). Chronic-weight- management indication, ~9.8% TBWL at 56 weeks, retains DEA Schedule IV and adds topiramate REMS.
• Patient on phentermine kickstart wants to transition to chronic therapy: Common real-world sequence is 12 weeks of phentermine followed by a GLP-1 (Wegovy if non-diabetic, Ozempic if T2D). See phentermine + GLP-1 combinations for the dual-therapy and sequencing literature.

For patients exploring the FDA-approved appetite-suppressant landscape more broadly, see the best FDA-approved appetite suppressant review, which covers phentermine, Qsymia, Contrave, liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound). For the full GLP-1 medication landscape, see the full GLP-1 medication reference.

How to access each drug

Both drugs are prescription-only in the United States. Access pathways differ because of the controlled-substance overlay on phentermine.

Phentermine requires a DEA-registered prescriber. In-person primary care, obesity-medicine clinics, and a subset of telehealth platforms with DEA-registered clinicians prescribe phentermine; the prescription is then filled at any retail or mail-order pharmacy that stocks the generic. See how to get a phentermine prescription online for the verified-telehealth-platform list and the regulatory details. Lomaira (8 mg three-times-daily) is an FDA-approved low-dose alternative reviewed in our Lomaira evidence review.

Ozempic is prescribed by any licensed prescriber without a DEA-registration overlay. Access pathways are primary care, endocrinology, obesity-medicine clinics, GLP-1 telehealth platforms, and NovoCare Pharmacy direct-pay for self-pay patients. For broader access pattern guidance, see the GLP-1 medication reference.

Bottom line

• Different drug classes. Phentermine is a 1959-approved sympathomimetic stimulant (amphetamine analog); Ozempic is a 2017-approved GLP-1 receptor agonist peptide. The two share an appetite-suppressing outcome through different molecular machinery.
• Different FDA labels. Phentermine is FDA-approved for short-term use only (typically up to 12 weeks); Ozempic is FDA-approved for long-term type 2 diabetes therapy with a cardiovascular risk-reduction indication.
• Different magnitudes. Phentermine produces ~3-5% TBWL at 12 weeks; semaglutide 2.4 mg produces -14.9% TBWL at 68 weeks (STEP-1). Ozempic at the T2D doses produces about -4 to -6 kg at 30 weeks as a secondary endpoint in glycemic-control trials.
• Different DEA status. Phentermine is a Schedule IV controlled substance with refill caps and DEA-registered-prescriber requirements; Ozempic is not a controlled substance.
• Different safety profiles. Phentermine’s stimulant mechanism raises heart rate and blood pressure and is contraindicated in established CV disease; Ozempic’s dominant adverse events are GI, and the drug holds a CV risk-reduction indication in T2D with CV disease.
• Different costs. Generic phentermine is ~$10-30/month; Ozempic is $499/month NovoCare self-pay and ~$1,000/month full retail. The 30-50x price gap tracks the patent status, route of administration, and cardiovascular-outcomes evidence base.
• Different patients. Phentermine answers short-term weight-loss-kickstart questions; Ozempic answers long-term type-2-diabetes questions. For long-term chronic weight management without T2D, the on-label molecule is Wegovy (the higher-dose semaglutide label).

Frequently asked questions

Related research

• Qsymia (phentermine + topiramate) evidence review — the FDA-approved chronic-weight-management combination that sits between phentermine monotherapy and GLP-1s.
• Lomaira (phentermine 8 mg TID) evidence review — the FDA-approved low-dose, divided-schedule alternative to Adipex-P 37.5 mg once daily.
• Can you take phentermine with a GLP-1? — published case-series evidence and prescriber considerations for the dual-therapy and sequencing questions.
• How to get a phentermine prescription online — verified-telehealth-platform list and the DEA-registered-prescriber regulatory framework.
• Wegovy vs Ozempic evidence review — same semaglutide molecule, different FDA-approved doses and indications; the comparison that follows once a patient has chosen the GLP-1 class.
• Best FDA-approved appetite suppressant — the full landscape including phentermine, Qsymia, Contrave, Saxenda, Wegovy, and Zepbound.
• Full GLP-1 medication list reference — every FDA-approved GLP-1 with brand, manufacturer, indication, dose ladder, and DailyMed SetID links.

Important disclaimer. This article is educational information only — not medical advice and not a substitute for consultation with a licensed prescriber. Phentermine is a DEA Schedule IV controlled substance with cardiovascular and psychiatric contraindications; Ozempic is a prescription injectable with a boxed warning for thyroid C-cell tumors. Every clinical decision involving either drug must be made with a licensed prescriber who has reviewed the full FDA prescribing information and the individual patient’s history. Every regulatory claim in this article is anchored to a primary source (DailyMed, PubMed, or the Code of Federal Regulations). Weight Loss Rankings does not prescribe, dispense, or endorse any specific medication or pharmacy.